Among the erlotinib-resistant variants derived from PC9, another lung adenocarcinoma cell line harboring an EGFR-activating mutation, PC9-ER1 and -ER3 exhibited upregulated ALDH1A1 (Supplementary Fig. S1H-J). This evidence concerns the gene EGFR and lung adenocarcinoma.